1. Home
  2. SCYX vs AGIG Comparison

SCYX vs AGIG Comparison

Compare SCYX & AGIG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$5.14

Market Cap

37.0M

Sector

Health Care

ML Signal

HOLD

Logo Abundia Global Impact Group Inc. Common stock

AGIG

Abundia Global Impact Group Inc. Common stock

HOLD

Current Price

$0.90

Market Cap

41.8M

Sector

Energy

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCYX
AGIG
Founded
1999
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Oil & Gas Production
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
37.0M
41.8M
IPO Year
2014
2025

Fundamental Metrics

Financial Performance
Metric
SCYX
AGIG
Price
$5.14
$0.90
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
239.4K
91.6K
Earning Date
05-06-2026
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
61.36
N/A
EPS
N/A
N/A
Revenue
$257,000.00
$410,632.00
Revenue This Year
N/A
N/A
Revenue Next Year
$608.78
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.57
$0.83
52 Week High
$5.62
$5.31

Technical Indicators

Market Signals
Indicator
SCYX
AGIG
Relative Strength Index (RSI) 62.82 44.78
Support Level $0.65 $0.83
Resistance Level $5.58 $1.10
Average True Range (ATR) 0.44 0.05
MACD 0.03 -0.00
Stochastic Oscillator 85.57 47.06

Price Performance

Historical Comparison
SCYX
AGIG

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About AGIG Abundia Global Impact Group Inc. Common stock

Abundia Global Impact Group Inc. is a technology solutions company operating in recycling, renewable energy, environmental change, fuels, and chemicals sectors, mainly focused on low-carbon energy solutions. The company uses waste plastics and biomass to produce crude or drop-in alternatives to fossil-derived energy, fuels, and chemicals through proprietary, licensed, and commercialized technologies, forming a complete process. It operates through its subsidiary and integrates feedstocks, technology, and off-take partners into a complete commercial chain. Its segments include Oil and Gas (O&G), which generates maximum revenue, and Renewables, which consists of its low-carbon fuels and renewable chemicals business.

Share on Social Networks: